INDUSTRY × Observational × Thoracic Neoplasms × Clear all
NCT04697446 2021-08-10

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Blueprint Medicines Corporation

Unknown
279 enrolled